Antineoplastics
1
Reactions 1440 - 23 Feb 2013 S Antineoplastics Neutropenia and febrile neutropenia in an elderly patient: case report A 69-year-old man developed neutropenia and febrile neutropenia while receiving chemotherapy with cisplatin, doxorubicin, vincristine and cyclophosphamide [routes, durations of treatment to reactions onset and outcomes not stated]. The man, whose medical history included diabetes mellitus, hypertension and pulmonary tuberculosis, was diagnosed with an anterior mediastinal tumour and HIV infection in June 2010. Histopathology revealed undifferentiated thymic carcinoma, and his final diagnosis was Masaoka stage IVb. He began receiving highly active antiretroviral therapy (HAART) with abacavir, lamivudine and raltegravir. Four courses of chemotherapy were started in August 2010, consisting of a drip infusion of cisplatin 50 mg/m 2 and doxorubicin 40 mg/m 2 on day 1, vincristine 0.6 mg/m 2 on day 3 and cyclophosphamide 700 mg/m 2 on day 4, every 4 weeks. He subsequently developed grade 4 neutropenia and febrile neutropenia. Non-haematological toxicities included grade 1 anorexia, alopecia and hiccups. At last follow-up, he was in a good general condition. Author comment: "During chemotherapy . . . neutropenia and febrile neutropenia were rapidly treated, enabling completion of four courses of ADOC [cisplatin, doxorubicin, vincristine and cyclophosphamide] therapy." Iriki T, et al. Chemotherapy for thymic carcinoma in an adult patient with HIV infection. International Cancer Conference Journal 1: 142-146, No. 3, Jul 2012. Available from: URL: http://dx.doi.org/10.1007/s13691-012-0027-0 - Japan 803083562 1 Reactions 23 Feb 2013 No. 1440 0114-9954/10/1440-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1440 - 23 Feb 2013
SAntineoplastics
Neutropenia and febrile neutropenia in an elderlypatient: case report
A 69-year-old man developed neutropenia and febrileneutropenia while receiving chemotherapy with cisplatin,doxorubicin, vincristine and cyclophosphamide [routes,durations of treatment to reactions onset and outcomes notstated].
The man, whose medical history included diabetes mellitus,hypertension and pulmonary tuberculosis, was diagnosed withan anterior mediastinal tumour and HIV infection in June 2010.Histopathology revealed undifferentiated thymic carcinoma,and his final diagnosis was Masaoka stage IVb. He beganreceiving highly active antiretroviral therapy (HAART) withabacavir, lamivudine and raltegravir. Four courses ofchemotherapy were started in August 2010, consisting of adrip infusion of cisplatin 50 mg/m2 and doxorubicin 40 mg/m2
on day 1, vincristine 0.6 mg/m2 on day 3 andcyclophosphamide 700 mg/m2 on day 4, every 4 weeks. Hesubsequently developed grade 4 neutropenia and febrileneutropenia. Non-haematological toxicities included grade 1anorexia, alopecia and hiccups. At last follow-up, he was in agood general condition.
Author comment: "During chemotherapy . . . neutropeniaand febrile neutropenia were rapidly treated, enablingcompletion of four courses of ADOC [cisplatin, doxorubicin,vincristine and cyclophosphamide] therapy."Iriki T, et al. Chemotherapy for thymic carcinoma in an adult patient with HIVinfection. International Cancer Conference Journal 1: 142-146, No. 3, Jul 2012.Available from: URL: http://dx.doi.org/10.1007/s13691-012-0027-0 -Japan 803083562
1
Reactions 23 Feb 2013 No. 14400114-9954/10/1440-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
